Genetic and molecular abnormalities of glioblastomas (GBM);Anomalies génétiques et moléculaires des glioblastomes (GBM)

Bulletin du Cancer

Volumn 97, Issue 11, 2010, Pages 1389-1407

  Larsen, C ^a  

^a NONE

Author keywords

Epigenetics; Exosomes; Glioblastomas; Tumor stem cells

Indexed keywords

MICRORNA;

ASTROCYTOMA; CANCER SUSCEPTIBILITY; EARLY CANCER; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC DISORDER; GENETIC PREDISPOSITION; GLIOBLASTOMA; HUMAN; MALIGNANT TRANSFORMATION; OLIGODENDROGLIOMA; REVIEW; TUMOR VASCULARIZATION;

EID: 78650117285     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1215     Document Type: Review

References (32)

1. In : Louis DN, Ohgaki H, Wiestler OD, Cavenne WK, eds. WHO classification of tumours of the central nervous system. Lyon, France : IARC Press, 2007.
2. Wager M, Karayan-Tapon L, Larsen CJ. Tumeurs du système nerveux central et périphérique. In : Lacave R, Larsen CJ, Robert J, eds. Cancérologie fondamentale. Paris : John Libbey Eurotext, 2006.
3. Cancer Genome Atlas Research Network. Comprehensive Genomic characterization defines human glioblastoma genes and core pathways. Nature 2008 ; 455 : 1061-8.
4. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Yuan Qi, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 2010 ; 17 : 98-110.
5. Vescovi AL, Galli R, Reynolds BA. Brain stem cells. Nat Rev Cancer 2006 ; 6 : 425-36.
6. Bao S, Wu Q, McLendon RE, Hao I, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA-damage response. Nature 2006 ; 444 : 756-60. (Pubitemid 44949604)
7. Penuelas S, Anido J, Orieto-Sanchez R, Folch G, Ignasi B, Cuartas I, et al. TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009 ; 15 : 315-27.
8. Chen RH, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest W, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010 ; 17 : 362-75.
9. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific predictors of chemotherapeutic response and survival in patients with anaplastic oligodendroglioma. J Natl Cancer Inst 1998 ; 90 : 1473-9. (Pubitemid 28482012)
10. Jenkins RB, Blair H, Ballman KV, Giannini C, Arussell RM, Law M, et al. A t(1;19)(p10;q10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006 ; 66 : 9852-61. (Pubitemid 44672036)
11. Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and is homozygously deleted in a subset of glioblastomas. Oncogene 2008 ; 27 : 2097-108. (Pubitemid 351442746)
12. Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, et al. Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci USA 2010 ; 107 : 6912-7.
13. Parsons DW, Jones S, Shang X, et al. An integrated genome analysis of human glioblastoma multiforme. Science 2008 ; 321 : 1807-12.
14. Gross S, Cairns RA, Minden MD, Drigger EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemias with isocitrate deshydrogenase 1 and 2 mutations. J Exp Med 2010 ; 207 : 339-44.
15. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, Von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008 ; 116 : 597-602.
16. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009 ; 174 : 1149-53.
17. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 activity and induce HIF-1α. Science 2009 ; 324 : 261-5.
18. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009 ; 462 : 739-44.
19. Aghili M, Zahedi F, Raffie E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol 2009 ; 91 : 233-6.
20. Jones DT, Kocialkowski Liu L, Pearson DM, Bäcklun d LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008 ; 68 : 8673-7.
21. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010 ; 140 : 209-21.
22. Hegi ME, Diserens AC, Gorlia T, Hamon MF, de Trilobet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005 ; 352 : 997-1003. (Pubitemid 40349502)
23. Carro MS, Link WK, Alvarez MJ, Bollo RJ, Zhao XD, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010 ; 463 : 318-25.
24. Li ZZ, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009 ; 15 : 501-13.
25. Tate MC, Aghi MK. Biology of angiogenesis and invasion in gliomas. Neurotherapeutics 2009 ; 6 : 447-57.
26. Ioro MV, Croce C. MicroRNAs in cancer: small molecules and huge impact. J Clin Oncol 2009 ; 27 : 5848-56.
27. Moore LM, Zhang W. Targeting miR-21 in glioma : a small RNA with a big potential. Exp Opin Ther Targets 2010 ; 14 : 1247-57.
28. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 2010 ; 107 : 2183-8.
29. Paunu N, Hermo P, Onkamo P, Ollikainen V, Rantala L, Helén EP, et al. A novel low-penetrance locus for familial glioma at 15q23-q26.3. Cancer Res 2002 ; 62 : 3798-802. (Pubitemid 34728864)
30. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008 ; 10 : 1470-6.
31. Pelloski PE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007 ; 25 : 2288-94. (Pubitemid 46954657)
32. Chaput N, Taïeb J, Andre F, Zitvogel L. The potential of exosomes in immunotherapy. Exp Opin Biol Ther 2005 ; 5 : 737-47.